GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Intrinsic Value: Projected FCF

RenovaCare (RenovaCare) Intrinsic Value: Projected FCF : $0.00 (As of May. 08, 2024)


View and export this data going back to . Start your Free Trial

What is RenovaCare Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-08), RenovaCare's Intrinsic Value: Projected FCF is $0.00. The stock price of RenovaCare is $0.0001. Therefore, RenovaCare's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for RenovaCare's Intrinsic Value: Projected FCF or its related term are showing as below:

RCAR's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.42
* Ranked among companies with meaningful Price-to-Projected-FCF only.

RenovaCare Intrinsic Value: Projected FCF Historical Data

The historical data trend for RenovaCare's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Intrinsic Value: Projected FCF Chart

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 - -0.08 -0.20 -0.30

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.30 -0.34 -0.38 -0.38

Competitive Comparison of RenovaCare's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, RenovaCare's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovaCare's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovaCare's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where RenovaCare's Price-to-Projected-FCF falls into.



RenovaCare Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get RenovaCare's Free Cash Flow(6 year avg) = $-3.27.

RenovaCare's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep22)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-3.26704+-1.46/0.8)/87.352
=-0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare  (OTCPK:RCAR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

RenovaCare's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/-0.37696182661051
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of RenovaCare's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovaCare (RenovaCare) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Executives
Patsy Trisler officer: Vice President 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold officer: President & CEO 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen director, officer: President & CEO 43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd. 10 percent owner 1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins director 406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace director, officer: President CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu director 5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper officer: President/ CEO
Frank J Fabio officer: CFO/Sec.(Resigned 1/9/2009) 670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson director 33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat director, 10 percent owner 700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong officer: President/CEO
Terri Dumoulin director, officer: Secretary/Treasurer

RenovaCare (RenovaCare) Headlines

From GuruFocus

RenovaCare Provides Clinical and Corporate Update

By GuruFocusNews GuruFocusNews 03-09-2022

RM LAW Announces Investigation of RenovaCare, Inc.

By PRNewswire PRNewswire 02-03-2022

RenovaCare Announces Management Changes

By GuruFocusNews GuruFocusNews 03-24-2022